poisar

Stock

Capricor Therapeutics, Inc. CAPR

$19.70-0.81%

Overview

CAPR market data

Price History

CAPR price chart

Valuation & Profitability

Twelve Data
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$2.26
Diluted earnings per share over the trailing twelve months.
Beta
0.40
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$4.30 – $40.37
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $1.1K · P/B 5.13 · P/S 50.37.

Company news

7 captured
8-K filing — CAPRICOR THERAPEUTICS, INC. (CAPR)SEC EDGAR · Jul 14, 2026, 9:06 PM
What's Going On With Capricor Therapeutics Stock On Friday?Benzinga · Jun 26, 2026, 6:10 PM
Capricor Therapeutics Announces FDA's Cellular, Tissue, And Gene Therapies Advisory Committee Intends To Call Advisory Committee Meeting To Discuss Capricor's BLA Of Deramiocel For Duchenne Muscular Dystrophy TreatmentBenzinga · Jun 26, 2026, 2:10 PM
Capricor Therapeutics To Present Data From Its Current HOPE-2 Open-Label Extension Trial Of Deramiocel For Duchenne Muscular Dystrophy At Parent Project Muscular Dystrophy 2026 Annual ConferenceBenzinga · Jun 26, 2026, 1:15 PM
Duchenne Muscular Dystrophy Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics LandscapeGlobenewswire Inc · May 26, 2026, 5:15 PM
HC Wainwright & Co. Reiterates Buy on Capricor Therapeutics, Maintains $60 Price TargetBenzinga · May 13, 2026, 11:08 AM
Capricor Therapeutics Q1 2026 Earnings Call TranscriptBenzinga · May 12, 2026, 9:35 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock